» Articles » PMID: 29022903

Alternative Mechanisms of MiR-34a Regulation in Cancer

Overview
Journal Cell Death Dis
Date 2017 Oct 13
PMID 29022903
Citations 124
Authors
Affiliations
Soon will be listed here.
Abstract

MicroRNA miR-34a is recognized as a master regulator of tumor suppression. The strategy of miR-34a replacement has been investigated in clinical trials as the first attempt of miRNA application in cancer treatment. However, emerging outcomes promote the re-evaluation of existing knowledge and urge the need for better understanding the complex biological role of miR-34a. The targets of miR-34a encompass numerous regulators of cancer cell proliferation, survival and resistance to therapy. MiR-34a expression is transcriptionally controlled by p53, a crucial tumor suppressor pathway, often disrupted in cancer. Moreover, miR-34a abundance is fine-tuned by context-dependent feedback loops. The function and effects of exogenously delivered or re-expressed miR-34a on the background of defective p53 therefore remain prominent issues in miR-34a based therapy. In this work, we review p53-independent mechanisms regulating the expression of miR-34a. Aside from molecules directly interacting with MIR34A promoter, processes affecting epigenetic regulation and miRNA maturation are discussed. Multiple mechanisms operate in the context of cancer-associated phenomena, such as aberrant oncogene signaling, EMT or inflammation. Since p53-dependent tumor-suppressive mechanisms are disturbed in a substantial proportion of malignancies, we summarize the effects of miR-34a modulation in cell and animal models in the clinically relevant context of disrupted or insufficient p53 function.

Citing Articles

Advancing Therapeutic Strategies with Polymeric Drug Conjugates for Nucleic Acid Delivery and Treatment.

Ullah A, Khan M, Zhang Y, Shafiq M, Ullah M, Abbas A Int J Nanomedicine. 2025; 20():25-52.

PMID: 39802382 PMC: 11717654. DOI: 10.2147/IJN.S429279.


Interleukin-6 Modulation in Ovarian Cancer Necessitates a Targeted Strategy: From the Approved to Emerging Therapies.

Amer H, Kampan N, Itsiopoulos C, Flanagan K, Scott C, Kartikasari A Cancers (Basel). 2025; 16(24.

PMID: 39766086 PMC: 11674514. DOI: 10.3390/cancers16244187.


A Novel Approach for Bladder Cancer Treatment: Nanoparticles as a Drug Delivery System.

Zhao X, Qi X, Liu D, Che X, Wu G Int J Nanomedicine. 2024; 19:13461-13483.

PMID: 39713223 PMC: 11662911. DOI: 10.2147/IJN.S498729.


Significant association of miRNA 34a with BRCA1 expression in pancreatic ductal adenocarcinoma: an insight on miRNA regulatory pathways in the Pakistani population.

Ali S, Adnan Y, Ahmad Z, Chawla T, Farooqui H, Adnan Ali S BMC Cancer. 2024; 24(1):1543.

PMID: 39696052 PMC: 11657824. DOI: 10.1186/s12885-024-13259-6.


Advancements in -Based Anti-Tumor Gene Therapy Research.

Peng Y, Bai J, Li W, Su Z, Cheng X Molecules. 2024; 29(22).

PMID: 39598704 PMC: 11596491. DOI: 10.3390/molecules29225315.


References
1.
Zhao L, Mao Y, Zhao Y, He Y . DDX3X promotes the biogenesis of a subset of miRNAs and the potential roles they played in cancer development. Sci Rep. 2016; 6:32739. PMC: 5009351. DOI: 10.1038/srep32739. View

2.
Kasinski A, Slack F . miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma. Cancer Res. 2012; 72(21):5576-87. PMC: 3488137. DOI: 10.1158/0008-5472.CAN-12-2001. View

3.
Jiang P, Liu R, Zheng Y, Liu X, Chang L, Xiong S . MiR-34a inhibits lipopolysaccharide-induced inflammatory response through targeting Notch1 in murine macrophages. Exp Cell Res. 2012; 318(10):1175-84. DOI: 10.1016/j.yexcr.2012.03.018. View

4.
Corney D, Hwang C, Matoso A, Vogt M, Flesken-Nikitin A, Godwin A . Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res. 2010; 16(4):1119-28. PMC: 2822884. DOI: 10.1158/1078-0432.CCR-09-2642. View

5.
Mori M, Triboulet R, Mohseni M, Schlegelmilch K, Shrestha K, Camargo F . Hippo signaling regulates microprocessor and links cell-density-dependent miRNA biogenesis to cancer. Cell. 2014; 156(5):893-906. PMC: 3982296. DOI: 10.1016/j.cell.2013.12.043. View